Evaluation of Iadademstat in the Management of Sickle Cell Disease in Affected Patients

The primary objective of this study is to evaluate the efficacy and safety of **IADADEMSTAT** in the treatment of **Sickle Cell Disease**. This is clinically relevant as Sickle Cell Disease is a genetic disorder characterized by abnormal hemoglobin, leading to chronic hemolytic anemia, vaso-occlusive crises, and potential organ damage. Effective treatment options are crucial to improve patient outcomes and quality of life. No secondary objectives are provided for this study.

The clinical trial involves participants diagnosed with **Sickle Cell Disease**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically encompass children and adolescents. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been specified. Key inclusion or exclusion criteria are not detailed in the available data.

The clinical trial is designed to evaluate the efficacy and safety of Iadademstat for the treatment of **Sickle Cell Disease**. This study is a Phase 3, randomized, double-blind, controlled trial. The trial is expected to commence recruitment on September 15, 2025, and is projected to conclude by January 1, 2100. Participants will be randomly assigned to either the treatment group receiving Iadademstat or a control group, with neither the participants nor the investigators aware of the group assignments to ensure unbiased results.

The trial will include several key study visits. Initially, a screening visit will be conducted to assess eligibility based on predefined inclusion and exclusion criteria. Following successful screening, participants will undergo a baseline visit where initial assessments and measurements will be recorded. Throughout the trial, participants will attend regular follow-up visits to monitor their health status, adherence to the treatment regimen, and any adverse events. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The end-of-study visit will mark the completion of the participant's involvement, during which final assessments will be conducted to evaluate the overall outcomes of the treatment.

The expected duration of participant involvement will vary depending on the individual's response to the treatment and adherence to the study protocol. Participants may be withdrawn from the study early if they experience significant adverse effects, fail to comply with the study requirements, or if the investigator deems it necessary for their safety. The trial's design and procedures are structured to ensure the collection of robust and reliable data while prioritizing participant safety and well-being.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements cannot be provided.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included in the data. As such, these aspects cannot be detailed in the context of this clinical trial description.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on September 15, 2025, with an estimated end date of January 1, 2100. The efficacy assessment will be conducted using predefined primary and secondary endpoints, although specific endpoints are not detailed in the available data. The trial will follow a structured methodology to ensure the accurate measurement and analysis of efficacy parameters. The trial's design and execution will adhere to rigorous standards to ensure the reliability and validity of the efficacy outcomes.